Mendel v CINN: São Paulo Court Dismisses Medical Bed Isolation Patent Appeal
Mendel Indústria, holder of two Brazilian patents covering contamination-isolating hospital beds with controlled temperature and humidity, prevailed as the Court of Justice of São Paulo dismissed competitor CINN Consultoria’s appeal and increased the loss fees owed to 15% of the updated conviction value.
São Paulo appellate court ends CINN’s challenge to Mendel’s hospital bed patents
This dispute before the Court of Justice of São Paulo centres on two Brazilian patents held by Mendel Indústria e Comércio de Equipamentos Médicos Hospitalares Ltda: utility model BRMU8401251U and invention patent BR102020017782B1. Both patents protect hospital bed systems designed to isolate patients from environmental contamination while maintaining controlled temperature and humidity parameters — technology with direct relevance to infection-control protocols in clinical and neonatal settings. The defendant, CINN Consultoria e Comércio de Equipamentos Hospitalares Ltda, is a competing supplier of hospital equipment.
The appellate court dismissed CINN’s appeal in its entirety and, notably, increased the loss fees owed by the appellant from the level set at first instance to 15% of the updated value of the conviction. This fee enhancement signals that the court found no merit in the grounds raised on appeal, reinforcing the first-instance ruling in favour of Mendel. The dismissal without a merits reversal means the underlying finding — and any enforcement measures attached to it — remains intact.
Because the filing date is not available in the public record, the total duration of proceedings cannot be determined from the available data. The fee increase imposed by the appellate panel is consistent with Brazilian civil procedure provisions penalising unsuccessful appeals, suggesting the court viewed the challenge as insufficiently founded. The precise damages quantum, the scope of any injunctive relief granted at first instance, and whether CINN may seek further review before a higher tribunal remain unknown from the public record.
Filing to Appeal Dismissed in 0 days
Case closed 25 June 2025; filing date not available in the public record
Appeal dismissed: what the São Paulo ruling means for both parties
What ‘appeal dismissed’ means in Brazilian civil procedure
A dismissal of the appeal by the Court of Justice of São Paulo means the appellate panel found no basis to disturb the first-instance decision. The lower court’s ruling stands in full. No merits reversal was issued. Additionally, the court exercised its discretion to increase loss fees to 15% of the updated conviction value — a penalty mechanism under Brazilian procedural law designed to discourage unmeritorious appeals.
First-instance ruling upheldMendel’s patents survive appellate challenge intact
For Mendel, the dismissal confirms that its hospital bed isolation patents — BRMU8401251U and BR102020017782B1 — remain enforceable as found by the first-instance court. The fee award enhancement further strengthens Mendel’s recovery position. Competitors and potential licensees should treat these patents as having withstood judicial scrutiny at the appellate level in São Paulo, raising the bar for any future challenge to their validity or scope.
Patents upheld; fees awardedCINN faces higher costs and narrower options after dismissal
CINN’s appeal failed without any merits relief. The court increased loss fees to 15% of the updated conviction value, adding financial exposure beyond the first-instance award. CINN’s options for further challenge within the São Paulo system are now constrained. Any further review would need to be sought before a superior tribunal, such as the Superior Court of Justice, on limited grounds — typically constitutional or statutory interpretation questions rather than factual re-examination.
Appeal costs elevatedStrengthened IP position for contamination-control bed technology in Brazil
The dismissal reinforces Mendel’s commercial position in the Brazilian market for isolation hospital beds. Competing suppliers should note that both a utility model and an invention patent covering this technology have now survived appellate review. For procurement teams and hospital equipment distributors, this ruling suggests that products replicating the contamination-isolation and climate-control features of Mendel’s beds carry meaningful infringement risk in Brazil.
Competitor risk elevated in BrazilFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Mendel Indústria and Comércio de Equipamentos Médicos Hospitalares Ltda | Individual | Medical hospital equipment manufacturer — holder of BRMU8401251U and BR102020017782B1Search in Eureka ↗ |
| Defendant | CINN Consultoria and Comércio de Equipamentos Hospitalares Ltda | Individual | Hospital equipment consultancy and trading company; appellant in this proceedingSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The court’s ruling — dismissing the appeal and increasing loss fees to 15% of the updated conviction value — is precise in its effect: the first-instance decision against CINN stands without modification on the merits, and CINN’s financial exposure is amplified. The fee enhancement is a discretionary appellate remedy under Brazilian procedural law, typically applied where the appellate grounds are found to lack substance. This phrasing leaves no ambiguity: no partial relief was granted to the appellant, and the underlying patent enforcement finding in Mendel’s favour is confirmed.
BRMU8401251U & BR102020017782B1 — Hospital Bed Contamination Isolation Systems
BRMU8401251U is a Brazilian utility model covering a bed system designed to isolate patients from external environmental contamination while controlling temperature and humidity parameters — technology with particular relevance to intensive care and infection-control settings. BR102020017782B1 is a Brazilian invention patent (B1 publication indicates grant) covering a cradle or stream bed variant with analogous isolation and climate-control features, likely directed at neonatal or specialised ward applications. Together, they represent a comprehensive IP position over a distinct category of hospital furniture.
The combination of a utility model and a granted invention patent covering adjacent embodiments of the same core technology is strategically significant. In Brazil, utility models offer a faster prosecution path and a 15-year term, while invention patents provide broader claim scope. Competitors developing or distributing isolation beds in Brazil must evaluate both patents independently. The appellate court’s refusal to disturb the first-instance ruling means that any product reproducing the contamination-isolation and climate-control architecture described in these patents carries elevated infringement risk in the Brazilian market.
Should your hospital bed product be cleared against BRMU8401251U and BR102020017782B1?
Any company manufacturing, importing, or distributing contamination-isolating hospital beds — including neonatal incubators or isolation cradles with temperature and humidity control — in Brazil should treat these two patents as live enforcement risks following this appellate ruling. The court’s dismissal of CINN’s appeal without merits relief means Mendel has now demonstrated willingness and success in enforcing these rights before the São Paulo judiciary. Procurement teams supplying Brazilian hospitals and R&D teams designing next-generation isolation bed systems are the primary audiences for an FTO assessment here.
PatSnap Eureka’s FTO Search Agent can map the claim scope of BRMU8401251U and BR102020017782B1 against your product specifications, identify design-around opportunities, and flag any related Brazilian patent filings by Mendel or third parties in the contamination-control bed space. Given that both a utility model and an invention patent are in play, a dual-track FTO analysis is advisable to assess risk under each title separately before entering or expanding in the Brazilian hospital equipment market.
Run a freedom-to-operate analysis on BRMU8401251U to assess your product’s exposure
Run FTO in Eureka →Similar Brazilian medical equipment patent disputes at São Paulo courts
Cases involving hospital equipment patents litigated before the Court of Justice of São Paulo, particularly in isolation and contamination-control medical device categories.
What this case signals for the Brazilian medical equipment IP landscape
The São Paulo appellate dismissal reinforces that Brazilian courts will uphold well-drafted hospital equipment patents and penalise unmeritorious appeals.
Brazilian appellate courts actively penalise weak patent appeals
The decision to increase loss fees to 15% of the updated conviction value is a clear signal. Brazilian civil procedure allows appellate courts to enhance fee awards when appeals lack merit. For patent defendants considering an appeal strategy in Brazil, this ruling suggests a high-quality evidentiary and legal basis is essential before challenging a first-instance finding.
Stacked patent protection — utility model plus invention patent — proved resilient
Mendel held both a utility model (BRMU8401251U) and a full invention patent (BR102020017782B1) covering overlapping aspects of its hospital bed technology. This layered approach to IP protection in Brazil appears to have contributed to a durable enforcement position. R&D teams developing medical equipment should consider filing both patent categories where Brazilian law permits.
Ltda v CINN — key questions answered
The Court of Justice of São Paulo dismissed CINN Consultoria’s appeal in full. The first-instance ruling in favour of Mendel Indústria — asserting patents BRMU8401251U and BR102020017782B1 — was upheld. The appellate court also increased the loss fees owed by CINN to 15% of the updated value of the conviction.
Two Brazilian patents are asserted: BRMU8401251U, a utility model covering a bed with contamination isolation and temperature/humidity control; and BR102020017782B1, a granted invention patent covering a cradle or stream bed with analogous isolation and climate-control features. Both patents are held by Mendel Indústria e Comércio de Equipamentos Médicos Hospitalares Ltda.
Dismissal of CINN’s appeal means no appellate relief was granted and the first-instance decision stands. CINN’s financial exposure increased because the court raised loss fees to 15% of the updated conviction value. Further challenge would require recourse to a superior tribunal — such as the Superior Court of Justice — on limited grounds, typically statutory or constitutional interpretation rather than factual review.
Under Brazilian civil procedure, appellate courts may increase loss fee awards when an appeal is found to lack sufficient merit. The court’s decision to raise fees to 15% of the updated conviction value is consistent with this mechanism and suggests the appellate panel found CINN’s grounds of appeal insufficiently founded to warrant any reduction or reversal of the first-instance ruling.
Competing suppliers of contamination-isolating hospital beds — particularly those incorporating temperature and humidity control features — face elevated infringement risk in Brazil following this ruling. Both BRMU8401251U and BR102020017782B1 have now survived appellate challenge, signalling that Mendel is prepared to enforce these patents. Distributors and manufacturers should conduct FTO assessments before supplying such products to Brazilian healthcare institutions.
PatSnap Eureka searches patents and litigation data to answer instantly.